Johnson & Johnson To Acquire Rights To Numab Therapeutics' Clinical-Stage Bispecific Antibody NM26
(RTTNews) - Johnson & Johnson (JNJ) announced Tuesday it has entered into a definitive agreement with biotechnology company Numab Therapeutics to acquire its wholly-owned subsidiary from Numab's shareholders in an all-cash transaction of approximately $1.25 billion.
The acquisition will give Johnson & Johnson the global rights to a novel, investigational first-in-class bispecific antibody, NM26.
NM26, which is ready to enter Phase 2 studies, targets two clinically proven pathways, IL-4R alpha subunit (IL-4Ra) and IL-31, in atopic dermatitis (AD). Atopic dermatitis, the most common inflammatory skin disease, is highly heterogeneous with different disease-driving mechanisms in distinct patient subpopulations.
In addition to potentially transforming the standard of care for AD, NM26 could also be efficacious in other inflammatory skin diseases involving Th2 inflammation and itch.
The closing of the transaction is expected to occur in the second half of 2024, following clearance under the Hart-Scott-Rodino Antitrust Improvements Act and satisfaction of other customary closing conditions. Accounting treatment will be communicated on or before the close of the transaction.
Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast
J&J Seeks EMA Approval For DARZALEX Quadruplet Therapy For Multiple Myeloma
AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial
Integra LifeSciences To Acquire Acclarent For $275 Mln Cash
Johnson & Johnson Guides FY24 Adj. EPS Below Estimates
Johnson & Johnson Trims FY23 Earnings, Net Sales Outlook
Court Rejects J&J Bankruptcy Petition To End Talc Cancer Lawsuits
